These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32706496)

  • 1. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
    Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
    J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.
    Oshige T; Nakamura Y; Sasaki Y; Kawano S; Ohki T; Tsuruta M; Tokubuchi I; Nakayama H; Yamada K; Ashida K; Tajiri Y; Nomura M
    Intern Med; 2019 Nov; 58(21):3125-3128. PubMed ID: 31243214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Lamos EM; Levitt DL; Munir KM
    Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child.
    Sakazume S; Obata K; Takahashi E; Yoshino A; Murakami N; Sakuta R; Murai T; Nagai T
    Eur J Pediatr; 2004 Aug; 163(8):472-4. PubMed ID: 15160292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
    Schwartz SS; Zangeneh F
    Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine: its place in type 2 diabetes Tx.
    Sando KR; Taylor J
    J Fam Pract; 2011 Nov; 60(11):E1-5. PubMed ID: 22049355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of migraine following bromocriptine treatment of a prolactinoma (pituitary microadenoma).
    Hartman N; Voron SC; Hershman JM
    Headache; 1995; 35(7):430-1. PubMed ID: 7672963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
    Roe ED; Chamarthi B; Raskin P
    J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
    Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
    Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
    Scranton R; Cincotta A
    Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    Yanto TA; Budiputri CL; Muljono MP; Chandra S
    J ASEAN Fed Endocr Soc; 2024; 39(1):95-105. PubMed ID: 38863918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
    Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
    J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
    Kabir MT; Ferdous Mitu J; Akter R; Akhtar MF; Saleem A; Al-Harrasi A; Bhatia S; Rahman MS; Damiri F; Berrada M; Rahman MH
    Environ Sci Pollut Res Int; 2022 Jul; 29(31):46385-46404. PubMed ID: 35486279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus.
    Kerr JL; Timpe EM; Petkewicz KA
    Ann Pharmacother; 2010 Nov; 44(11):1777-85. PubMed ID: 20978217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
    Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
    Zhang SL; Tang HB; Hu JT; Zang ZL; Ding X; Li S; Yang H
    Biomed Pharmacother; 2019 Mar; 111():638-648. PubMed ID: 30611988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.
    Orrego JJ; Chandler WF; Barkan AL
    Pituitary; 2000 Nov; 3(3):189-92. PubMed ID: 11383485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction].
    López Cubillana P; Hita Rosino E; Asensio Egea L; Rigabert Montiel M; Hita Villaplana G; Server Pastor G; Server Falgás G
    Arch Esp Urol; 1997 Jun; 50(5):526-8. PubMed ID: 9382597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.